title: Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque.
abstract: Rabies virus (RV) has recently been developed as a novel vaccine candidate for human immunodeficiency virus type 1 (HIV-1). The RV glycoprotein (G) can be functionally replaced by HIV-1 envelope glycoprotein (Env) if the gp160 cytoplasmic domain (CD) of HIV-1 Env is replaced by that of RV G. Here, we describe a pilot study of the in vivo replication and immunogenicity of an RV with a deletion of G (DeltaG) expressing a simian/human immunodeficiency virus SHIV(89.6P) Env ectodomain and transmembrane domain fused to the RV G CD (DeltaG-89.6P-RVG) in a rhesus macaque. An animal vaccinated with DeltaG-89.6P-RVG developed SHIV(89.6P) virus-neutralizing antibodies and SHIV(89.6P)-specific cellular immune responses after challenge with SHIV(89.6P). There was no evidence of CD4(+) T-cell loss, and plasma viremia was controlled to undetectable levels by 6 weeks postchallenge and has remained suppressed out to 22 weeks postchallenge.
authors.affiliation: Department of Microbiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Philip M
authors.initials: PM
authors.lastname: McKenna
authors.forename: Pyone Pyone
authors.initials: PP
authors.lastname: Aye
authors.forename: Bernhard
authors.initials: B
authors.lastname: Dietzschold
authors.forename: David C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: Louis N
authors.initials: LN
authors.lastname: Martin
authors.forename: Preston A
authors.initials: PA
authors.lastname: Marx
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Pomerantz
authors.forename: Andrew
authors.initials: A
authors.lastname: Lackner
authors.forename: Matthias J
authors.initials: MJ
authors.lastname: Schnell
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D000956:Antigens, Viral / Q000235:genetics*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D017353:Gene Deletion; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology*; D006023:Glycoproteins / Q000235:genetics*; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D008253:Macaca mulatta; D011820:Rabies virus / Q000235:genetics / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000276:immunology; D014611:Vaccination; D014759:Viral Envelope Proteins / Q000235:genetics*
chemical_list: D016915:AIDS Vaccines; D000956:Antigens, Viral; D015686:Gene Products, env; D006023:Glycoproteins; D015483:HIV Antibodies; D014759:Viral Envelope Proteins; C064951:glycoprotein G, Rabies virus